7. Indexation7. Indexation

7. Indexation

(1) At the start of 1 July 2025 (the indexation time), each amount covered by subsection (2) is replaced by the amount worked out using the following formula: 1.024 multiplied by the amount immediately before the indexation time Note: The indexed fees could in 2025 be viewed on the Department of Health and Aged Care’s MBS Online website (https://www.mbsonline.gov.au).

(2) The amounts covered by this subsection are the fee for each item in a Schedule of this Determination.

(3) An amount worked out under subsection (1) is to be rounded up or down to the nearest 5 cents (rounding down if the amount is an exact multiple of 2.5 cents).

Schedule 1 – relevant services

<table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><thead><tr><td colspan="3" style="border-top:1.5pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableHeading"><span>Group T1—Miscellaneous therapeutic procedures</span></p></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableHeading"><span>Subgroup 13 – Miscellaneous therapeutic procedures</span></p></td></tr><tr><td style="width:13.72%; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableHeading"><span>Column 1</span></p><p class="TableHeading"><span>Item</span></p></td><td style="width:69.44%; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableHeading"><span>Column 2</span></p><p class="TableHeading"><span>Description</span></p></td><td style="width:16.84%; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableHeading" style="text-align:right"><span>Column 3</span></p><p class="TableHeading" style="text-align:right"><span>Fee ($)</span></p></td></tr></thead><tbody><tr><td style="width:13.72%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext" style="margin-top:0pt"><a id="CU_5453681"></a><a id="CU_9455510"></a><a id="CU_18457523"></a><a id="CU_10459325"></a><span>14247</span></p></td><td style="width:69.44%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext" style="margin-top:0pt; line-height:normal"><span>Extracorporeal photopheresis for the treatment of erythrodermic stage III</span><span>‑</span><span>IVa T4 M0 cutaneous T</span><span>‑</span><span>cell lymphoma; if</span></p><p class="Tabletext" style="margin-top:0pt; margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(a)</span><span style="width:6.9pt; text-indent:0pt; display:inline-block"> </span><span>the service is provided in the initial six months of treatment; and</span></p><p class="Tabletext" style="margin-top:0pt; margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(b)</span><span style="width:6.34pt; text-indent:0pt; display:inline-block"> </span><span>the service is delivered using an integrated, closed extracorporeal photopheresis system; and</span></p><p class="Tabletext" style="margin-top:0pt; margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(c)</span><span style="width:6.9pt; text-indent:0pt; display:inline-block"> </span><span>the patient is 18 years old or over; and</span></p><p class="Tabletext" style="margin-top:0pt; margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(d)</span><span style="width:6.34pt; text-indent:0pt; display:inline-block"> </span><span>the patient has received prior systemic treatment for this condition and experienced either disease progression or unacceptable toxicity while on this treatment; and</span></p><p class="Tabletext" style="margin-top:0pt; margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(e)</span><span style="width:6.9pt; text-indent:0pt; display:inline-block"> </span><span>the service is provided in combination with the use of Pharmaceutical Benefits Scheme</span><span>‑</span><span>subsidised methoxsalen; and</span></p><p class="Tabletext" style="margin-top:0pt; margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(f)</span><span style="width:8.01pt; text-indent:0pt; display:inline-block"> </span><span>the service is supervised by a specialist or consultant physician in the speciality of haematology.</span></p><p class="Tabletext" style="margin-top:0pt; line-height:normal"><span></span></p><p class="Tabletext" style="margin-top:0pt; line-height:normal"><span>Applicable once per treatment cycle (H)</span></p></td><td style="width:16.84%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext" style="margin-top:0pt; text-align:right"><span>1,925.55</span></p></td></tr><tr><td style="width:13.72%; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext"><span>14249</span></p></td><td style="width:69.44%; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext" style="margin-top:0pt; line-height:normal"><span>Extracorporeal photopheresis for the continuing treatment of erythrodermic stage III</span><span>‑</span><span>IVa T4 M0 cutaneous T</span><span>‑</span><span>cell lymphoma; if</span></p><p class="Tabletext" style="margin-top:0pt; margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(a)</span><span style="width:6.9pt; text-indent:0pt; display:inline-block"> </span><span>in the preceding 6 months:</span></p><p class="Tabletext" style="margin-top:0pt; margin-left:54pt; text-indent:-18pt; line-height:normal"><span>(i)</span><span style="width:8.56pt; text-indent:0pt; display:inline-block"> </span><span>a service to which item</span><span> </span><span>14247 applies has been provided; and</span></p><p class="Tabletext" style="margin-top:0pt; margin-left:54pt; text-indent:-18pt; line-height:normal"><span>(ii)</span><span style="width:5.78pt; text-indent:0pt; display:inline-block"> </span><span>the patient has demonstrated a response to this service; and</span></p><p class="Tabletext" style="margin-top:0pt; margin-left:54pt; text-indent:-18pt; line-height:normal"><span>(iii)</span><span style="width:3pt; text-indent:0pt; display:inline-block"> </span><span>the patient requires further treatment; and</span></p><p class="Tabletext" style="margin-top:0pt; margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(b)</span><span style="width:6.34pt; text-indent:0pt; display:inline-block"> </span><span>the service is delivered using an integrated, closed extracorporeal photopheresis system; and</span></p><p class="Tabletext" style="margin-top:0pt; margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(c)</span><span style="width:6.9pt; text-indent:0pt; display:inline-block"> </span><span>the patient is 18 years old or over; and</span></p><p class="Tabletext" style="margin-top:0pt; margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(d)</span><span style="width:6.34pt; text-indent:0pt; display:inline-block"> </span><span>the service is provided in combination with the use of Pharmaceutical Benefits Scheme</span><span>‑</span><span>subsidised methoxsalen; and</span></p><p class="Tabletext" style="margin-top:0pt; margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(e)</span><span style="width:6.9pt; text-indent:0pt; display:inline-block"> </span><span>the service is supervised by a specialist or consultant physician in the speciality of haematology.</span></p><p class="Tabletext" style="margin-top:0pt; margin-left:36pt; line-height:normal"><span></span></p><p class="Tabletext" style="margin-top:0pt; line-height:normal"><span>Applicable once per treatment cycle (H)</span></p></td><td style="width:16.84%; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext" style="text-align:right"><span>1,925.55</span></p></td></tr></tbody></table>